Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma by unknown
ORIGINAL ARTICLE
Antithrombin III is probably not a suitable biomarker
for diagnosis of primary central nervous system lymphoma
Milla Elvi Linnea Kuusisto & Kirsi-Maria Haapasaari &
Anne Marja Remes & Risto Bloigu & Peeter Karihtala &
Taina Turpeenniemi-Hujanen & Outi Kuittinen
Received: 23 August 2014 /Accepted: 4 February 2015 /Published online: 21 February 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Antithrombin III (AT III) in cerebrospinal fluid
(CSF) has been suggested to have high specificity and sensi-
tivity in separating primary central nervous system (CNS)
lymphoma from other neurological conditions. We measured
with ELISA CSF and serum AT III and albumin levels in 12
lymphoma patients with CNS involvement, 30 lymphoma pa-
tients without CNS involvement, and 41 patients with non-
neoplastic neurological diseases. AT III immunostaining was
also carried out, in lymphoma patients. Both CSF AT III and
albumin levels were higher in lymphoma patients with CNS
involvement. AT III/albumin ratio in CSF was the most sen-
sitive and specific measure for diagnosis. Lowest it was in
patients with known CNS lymphoma. Serum AT III levels
were lower both in CNS lymphoma and systemic lymphoma.
CSF AT III levels were shown to be higher in lymphoma
patients with CNS involvement, when AT III/albumin ratios
were lower. This was probably a result of lowered serum AT
III levels, indicating that high levels of AT III in CSF might
reflect only leakage of the blood–brain barrier. Thus, AT III
fails to be a specific marker for diagnosis of lymphoma CNS
involvement.
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Introduction
About 2 % of all systemic lymphomas are primary cen-
tral nervous system (CNS) lymphomas (PCNSLs). These
are rapidly progressing diseases with often fatal out-
come despite the use of high-dose methotrexate-contain-
ing treatment regimens [1]. Usually, the diagnosis of
PCNSL is based on a histological sample taken by ste-
reotactic biopsy. However, sometimes in the early stage
of the disease, there is no radiologically apparent target
tissue for the biopsy or the disease may mimic another
neurological disorders. Cerebrospinal fluid (CSF) has
also been used in the diagnostic and differential process,
although the associated cytology is not sensitive and the
results can be negative in up to 60 % of the patients [2,
3]. The disease is rapidly progressing; there is a need
for urgent diagnostic work-up and start of therapy.
There is also a need for sensitive and specific bio-
markers for early diagnosis.
In addition to the above, lymphomas presenting pri-
marily as systemic disease may recur in the CNS. The
prognosis in cases of CNS relapse is dismal. At least
5 % of patients with diffuse large B cell lymphoma
(DLBCL) will develop CNS involvement if appropriate
prophylactic therapy is not given [2]. Early CNS re-
lapses probably arise from subclinical CNS disease al-
ready present at the time of the primary diagnosis. Pro-
phylactic therapies cannot be given to all patients with
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systemic lymphoma as a result of the high toxicity rate.
There is an unmet clinical need for good biomarkers for
selection of DLBCL patients with subclinical CNS in-
volvement for prophylactic therapies.
Antithrombin III (AT III) is a protein produced by hepato-
cytes, and its physiological role is to play a part in the normal
anticoagulation system [4–6]. AT III has also been detected in
CSF [6–9].
It was suggested in a paper by Roy et al. that AT III in CSF
is a specific biomarker of PCNSL, and more accurate in iden-
tification of CNS lymphoma than CSF cytology [7, 8]. The
author also suggested that AT III level alone is sufficient for a
diagnosis of PCNSL. However, increased concentrations of
AT III in CSF might merely reflect leakage of the blood–brain
barrier [9].
The aim of the present study was to evaluate whether
or not CSF AT III is an independent biomarker of lym-
phoma CNS lesions or a marker of blood–brain barrier
leakage, and whether it could be used to find patients
with systemic lymphoma and subclinical CNS disease.
The biology of AT III was also explored to see if it is
present in endothelial and/or lymphoma cells, to discov-
er the possible origin of CSF AT III.
Materials and methods
Patients and sample collection
The lymphoma study samples were taken from patients treat-
ed at Oulu University Hospital during 2009–2012 after receiv-
ing written informed consent in each case. All patients suf-
fered from histologically confirmed lymphoma. The clinical
data was collected carefully from hospital records. The prin-
ciples of Declaration of Helsinki were followed in this study.
Ethical resolution was applied from the Local Ethics Commit-
tee of the Northern Ostrobothnia Hospital District and from
National Supervisory Authority for Welfare and Health
(Valvira). Valvira permission number was 6622/05.01.00.06/
2010.
Patient details are presented in Table 1. The patients were
selected for this study because of the availability of their CSF,
which was taken during normal lymphoma diagnostic and
therapeutic procedures. Samples from patients without CNS
disease were taken while treating them by means of routine
prophylactic intrathecal therapy. Prophylactic therapy includ-
ed administration of high-dose methotrexate given intrave-
nously and intrathecally, or simply intrathecally. The
Table 1 Demographics of the patients
Patients with systemic
lymphoma and CNS lesion
Patients with systemic




Median (years) 71 57 62
Range (years) 70–79 18–81 50–75
Sex
Male 5 (71.4 %) 13 (44.8 %) 3 (60 %)
Female 2 (28.6 %) 16 (55.2 %) 2 (40 %)
Lymphoma subtype
DLBCL 6 (85.7 %) 16 (55.2 %) 2 (40 %)
Mantle cell lymphoma 1 (14.3 %) 0 0
Atypical Burkitt’s lymphoma 0 8 (27.6 %) 2 (40 %)
Burkitt’s lymphoma 0 1 (3.4 %) 0
T-cell-rich B cell lymphoma 0 1 (3.4 %) 0
Follicular lymphoma 0 2 (6.9 %) 1 (20 %)
Lymphocytic lymphoma 0 1 (3.4 %) 0
Patients with Alzheimer’s disease Patients with multiple sclerosis Patients with no neurological illness
(n=19) (n=7) (n=37)
Age
Median (years) 61 39 49
Range (years) 51–70 31–46 26–73
Sex
Male 9 (47.4 %) 3 (42.9 %) 20 (54.1 %)
Female 10 (52.6 %) 4 (57.1 %) 17 (45.9 %)
PCNSL primary central nervous system lymphoma, DLBCL diffuse large B cell lymphoma
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prophylaxis was given to patients with International Prognos-
tic Index of 3–5 and to patients with testicular, paraspinal, or
breast location of lymphoma. One of the patients in the present
study was given intrathecal methotrexate and four were given
both intravenous and intrathecal methotrexate before CSF
samples were taken. Assays of CSF and serum albumin con-
centrations were performed as part of normal laboratory rou-
tines. For CSF AT III assay, only samples taken via lumbar
puncture were included. Macroscopically bloody samples
were excluded. Standardization of sample taking was ensured
by using only one physician for the procedure. Three cases
were excluded because CSF was taken via a reservoir used for
intrathecal therapy. The serum samples from these patients,
however, were included in the evaluation. Matched CSF and
serum samples were available in 15 cases. Altogether, 42 CSF
samples and 18 serum samples were available for analysis.
Immunohistochemical analysis was carried out using lympho-
ma tissue samples from the same patients.
As a control group, 42 CSF samples were collected from
patients with non-neoplastic neurological diseases (all taken
by lumbar puncture). These were 19 cases with clinically,
genetically, or autopsy-confirmed Alzheimer’s disease, 6 pa-
tients with multiple sclerosis (MS) diagnosed according to
McDonald’s 2005 criteria [10] and also with MS-typical
CSF findings, and 17 cases who suffered from subjective
memory problems connected with depression without any
signs of progressive neurodegenerative disease or neurologi-
cal condition within 3 years of follow-up. Serum samples
from these cases were not available. These samples were col-
lected at the Department of Neurology, Kuopio University
Hospital during normal diagnostic procedures. Patient details
are shown in Table 1. Twenty serum samples taken from
healthy controls were also available.
ELISAs
Antithrombin III concentrations in CSF were detected by
using an ELISA. Commercial assay kits (Human Antithrom-
bin III ELISA kit, cat. No. KSP-110, Nordic BioSite, Täby,
Sweden) were used. The principles of this assay have been
described previously [11], and kits were used according to the
manufacturer’s instructions. The method is based on a quan-
titative enzyme immunoassay technique. In this assay, AT III
in standards and samples is sandwiched between immobilized
antibody and biotinylated polyclonal antibody specific for AT
III, and the complex is recognized by a streptavidin-
peroxidase conjugate.
Blood was collected in siliconized 3.5-ml glass containers
containing one part serum gel solution. Serum was prepared
from blood by centrifugation at 1500×g for 10 min. AT III
concentrations were measured by ELISA (Human Antithrom-
bin III ELISA kit, cat. no. KSP-111, Nordic BioSite, Täby,
Sweden) according to the manufacturer’s instructions. In this
assay, standards and samples are competed with a biotinylated
AT III sandwiched by the immobilized antibody and
streptavidin-peroxidase conjugate.
Immunohistochemistry
For immunohistochemical analyses, 42 tissue samples were
available. Most of them were lymph node biopsy samples, but
brain and ventricle biopsy samples were also present (lymph
nodes, n=38; brain, n=3; ventricle, n=1). All tissue samples
had been surgically removed from patients during normal di-
agnostic procedures and used for the study later. Immuno-
staining was performed as described previously [12], with a
few modifications: Novolink kits were used according to the
manufacturer’s instructions. Antibody dilution was 1:35.
Samples were microwaved with Tris-EDTA, pH 9, and incu-
bated at room temperature for 1 h before immunostaining with
a commercial polyclonal antithrombin III antibody (Novus
Biologicals, Littleton, USA).
Statistical analysis
Statistical analysis was performed using SPSS Data Editor
Software version 20 (IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, version 20.0. Armonk, NY). Contin-
uous variables with normal distributions were compared by
using independent samples t tests. Serum AT III and albumin
concentrations showed normal distributions. Continuous var-
iables with skewed distributions were compared by using the
Mann–Whitney U test. Because CSFAT III and albumin con-
centrations did not show normal distributions, median values
were used for comparison. Values of p<0.05 were considered
to be statistically significant.
Results
The median age of the patients with lymphoma (21 males, 21
females) was 62.5. The non-lymphoma patients (32 males, 31
females) were somewhat younger (median age 52).
AT III and albumin concentrations in cerebrospinal fluid
The median CSF AT III concentration was found to be
1.47 μg/ml (range 0.49–6.91) in the lymphoma patients, and
it was 1.08 μg/ml (0.50–4.05) in the group of patients with
non-neoplastic neurological disorders (Table 2). The differ-
ence between these two groups was statistically highly signif-
icant (p=0.002, in Mann–Whitney U test). The median albu-
min concentration in the CSF of patients with lymphoma was
243 mg/l (52.5–9727), and it was 193 mg/l (105.5–1099) in
the non-lymphoma group. This difference was not statistically
significant (p=0.219). Concentrations of CSFAT III were also
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compared in different patient groups (Fig. 1a). When compar-
ing CSF AT III concentrations in patients with PCNSL with
those in patients with secondary CNS lymphoma or lympho-
ma patients without CNS lesions, or with the non-lymphoma
group of patients, a statistically significant difference was seen
indicating that CSF AT III concentrations were highest in the
group of PCNSL patients (p=0.006). Concentrations of CSF
AT III were also compared in patients with CNS lymphoma
(including PCNSL patients and patients with CNS-relapsed
systemic lymphoma) versus those with non-neoplastic neuro-
logical diseases. In this comparison, in patients with CNS
lymphoma, CSF AT III concentrations remained still higher
(p=0.009), as seen in Fig. 1b. Similar differences were found
when the same groups were compared to CSF albumin con-
centrations, although in patient group of PCNSL, albumin
concentrations were much higher than in other patient groups
(Fig. 1c, p=0.006). We compared CSF AT III concentrations
in patients with MS disease with those in lymphoma patients
with CNS involvement (both primary and secondary), and the
concentrations were rather similar (p=0.167). When compar-
ing CSF AT III concentrations between groups of lymphoma
patients with CNS involvement (both primary and secondary)
versus lymphoma patients with systemic disease only, no dif-
ferences were found (p=0.126).
The AT III/ albumin ratio was calculated as reported previ-
ously [9]. When comparing this ratio in the different groups of
patients with PCNSL, secondary CNS lymphoma, systematic
lymphoma without CNS involvement, and non-lymphoma
patients (Fig. 1d), patients with systemic lymphoma without
CNS lesion had the highest AT III/albumin ratio (p<0.001).
Fig. 1 Cerebrospinal fluid (CSF) antithrombin III (AT III) and albumin
concentrations and AT III/ albumin concentration ratio in different patient
groups. a AT III concentrations in patients with primary CNS lymphoma
(PCNSL), secondary CNSL (sCNSL), systemic lymphoma, and non-
neoplastic disease as a control group of patients. b AT III concentrations
in patients with CNS lymphoma (both PCNSL and sCNSL), multiple
sclerosis (MS) disease, Alzheimer’s disease, and in control group pa-
tients. c Albumin concentrations in patients with PCNSL, sCNSL, sys-
temic lymphoma without CNS lesion, and non-neoplastic disease as a
control group of patients. d AT III/albumin ratio in patients with PCNS
L, sCNSL, systemic lymphoma without CNS lesion, and non-neoplastic
disease as a control group of patients
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AT III and albumin concentrations in serum
Antithrombin III and albumin concentrations were also
assayed in serum, as shown in Table 2. The mean serum AT
III concentration in patients with lymphoma was 0.021 mg/ml
(range 0.01–0.03) and 0.03 mg/ml (0.02–0.04) in the non-
lymphoma group. The difference between these two groups
was statistically significant (p<0.001). The mean serum albu-
min level was 40.94 g/l (26–49) in patients with lymphoma
and 44.55 g/l (37–49) in the non-lymphoma group. This dif-
ference was also statistically significant (p=0.029).
Correlations between AT III immunostaining and serum
and CSFAT III levels
The amount of immunoreactive protein staining was analyzed
in three separate groups; tumor cytoplasm, tumor nuclear
membrane, and tumor vasculature. In Fig. 2a, the immunohis-
tochemical (IHC) results are compared with respective CSF
AT III concentrations. Moderate and strong expression of cy-
toplasmic AT III in lymphoma cells (Fig. 2b) correlated with
high concentrations of AT III in the CSF. The same kind of a
trend was also seen as regards the nuclear membrane expres-
sion of AT III. However, endothelial expression in tumor vas-
culature did not correlate with AT III concentrations in the
CSF. Serum AT III levels were also compared with IHC re-
sults. Lower AT III concentrations in the serum correlated
with moderate and strong expression of AT III both in tumor
cytoplasm and on nuclear membranes (p=0.036 and p=0.037,
Fig. 2c). There was no statistically significant correlation
when comparing the AT III levels with staining in tumor
vasculature.
Receiver operating characteristic curves
We evaluated receiver operating characteristic (ROC) curves
of CNS lymphoma patients, including both primary and sec-
ondary CNS lymphomas, versus patients with non-neoplastic
neurological disorders. All diagnostic tests yielded somewhat
similar results: CSFAT III/albumin ratio had area under curve
(AUC) 0.250 (p=0.009), CSF AT III alone had AUC 0.791
(p=0.002), and CSF albumin had AUC 0.839 (p<0.001)
(Fig. 3). 0-hypothesis was AUC 0.500, and values close to
1.000 are found significant and possibly useful as biomarkers
in ROC analysis.
Discussion
In the present study, we found that CSFAT III concentrations
were higher in patients with CNS lymphoma compared with
patients with non-neoplastic neurological diseases. However,
the values overlapped with each other, indicating that the
specificity of CSF AT III measurement for CNS lymphoma
is not valid for clinical use. Moreover, high CSF albumin
levels had better specificity for CNS lymphoma than did
CSF AT III levels. The most specific test to separate groups
with lymphoma CNS involvement from other patient groups
was the CSF AT III/ albumin ratio. Surprisingly, low ratios
predicted the existence of primary or secondary CNS lympho-
ma. To study further the reason for these low ratio levels, we
also measured the serum AT III concentrations. We found low
serum AT III levels in lymphoma patients, which might ex-
plain the low CSF AT III/ albumin ratio in these patients. In
MS in which the blood–brain barrier is probably leaking [13],
the concentrations of AT III in the CSF were only slightly
higher than in other neurological groups. There was no statis-
tically significant difference when comparing CSFAT III con-
centrations in MS patients with those in lymphoma patients
with CNS involvement (p=0.167). Taken together, these find-
ings indicate that CSFAT III might reflect only a blood–brain
barrier leakage, and it may not be an independent marker of
CNS lymphoma.
Antithrombin III is a physiological anticoagulative protein
produced by hepatocytes [6]. It is involved both in intravas-
cular and extravascular coagulation, and it is present normally
Table 2 Cerebrospinal fluid (CSF) and serum antithrombin III (AT III) and albumin levels
Patients with lymphoma Non-lymphoma patients
(n=42) (n=61)
Characteristic Median Number Range Median Number Range p
Age (years) 62.50 42 18–81 52 61 26–70 0.001a
CSFAT III (μg/ml) 1.471 42 0.49–6.91 1.077 41 0.50–4.05 0.002a
CSF albumin (mg/l) 242.82 42 52.51–9727.70 192.77 41 105.52–1099.02 0.219a
Serum AT III (mg/ml) 0.0213 18 0.01–0.03 0.0296 20 0.02–0.04 0.001b
Serum albumin (g/l) 40.944 18 26–49 44.55 20 37–49 0.029b
aMann–Whitney U test
b Independent samples t test
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in blood and lymph both in soluble form and bonded to
thrombin-forming reversible AT III–thrombin complexes [6,
14]. AT III immunoreactive protein has been found previously
in lymphoma cells [7]. Similar findings were also seen in the
present study in lymphoma tissue samples both from brain and
other tissues. Rubenstein et al. [7, 8, 15] evaluated AT III
production in diagnostic PCNSL samples by gene expression
profiling and suggested that lymphoma cells could produce
the AT III. Due to the diffuse spread of malignant lymphocytes
in the CNS, it is impossible, however, to specify exactly from
which cells the AT III might be derived originally, and the
knowledge of AT III biology in CSF is also so far incomplete
[16]. Moreover, there are reports showing that AT III can
detach from endothelial cells. This might be the best explana-
tion for AT III positivity in the CNS [17].
There have been several studies on cancer patients in which
changes in serum AT III levels have been investigated, with
variable results [5, 6, 18, 19]. In studies including patients
with lymphoma, lowered serum AT III concentrations have
been discovered in active disease [18]. Successful treatment
seems to normalize values, but there are still statistically sig-
nificant differences between groups of lymphoma patients
versus controls [18].
In our study, we detected lowered serum AT III concentra-
tions in lymphoma patients, which may be caused by either
increased use or decreased production [18]. We also found a
correlation between lowered serum AT III concentrations and
moderate and strong cytoplasmic and nuclear membrane AT
III positivity in immunohistochemistry, suggesting that serum
AT III concentrations decrease while lymphocytes accumulate
Fig. 3 Receiver operating
characteristic (ROC) curve
analysis of CNS lymphoma
patients, including both primary
and secondary CNS lymphomas,
versus patients with non-
neoplastic neurological disorders
to evaluate the possible role of
antithrombin III (AT III) in
cerebrospinal fluid (CSF) to be a
novel biomarker to separate CNS
lymphomas from other
neurological disorders. 0-
hypothesis was area under curve
(AUC) 0.500, and values close to
1.000 are found significant and
possibly useful as biomarkers in
ROC analysis
Fig. 2 a Tumor cell antithrombin III (AT III) immunoreactivity reverse
correlation with serumAT III concentrations. b Immunohistochemistry of
lymphoma tissue, demonstrating tumor cell cytoplasmic expression of AT
III and also AT III staining positivity around capillaries. Antithrombin III
antibody staining, ×40 magnification. c Immunohistochemistry of
lymphoma tissue, demonstrating strong expression of AT III in tumor
cell cytoplasm and nuclear membrane. Antithrombin III antibody
staining, ×100 magnification
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AT III. Because there is elevated thrombin production in can-
cer patients, there could also be elevated consumption of AT
III in serum. In addition, the fact that AT III can detach from
endothelial cells and then bond with soluble thrombin [17]
could indicate elevated consumption of AT III in lymphoma
patients similarly as found in other cancer patients.
In a previous study by Roy et al., a mean CSFAT III level
of 3.1 μg/ml was reported in CNS lymphoma patients and a
mean value of 0.53 μg/ml in control patients without lympho-
ma [7]. In the present study, concentrations in the CSF did not
follow a normal distribution and median values were used for
evaluation. The median concentrations among our patients
were 1.5 μg/ml (range 0.49–6.91) in those with lymphoma
and 1.1 μg/ml (0.50–4.05) in the control group patients. The
difference was statistically significant but the values overlap-
ped. However, the difference between lymphoma patients
with and without known CNS disease was also statistically
significant, indicating that in patients with known CNS lym-
phoma diagnosis, CSFAT III concentrations were higher (p=
0.006). It has been previously suggested that CSFAT III con-
centrations could allow differentiation of CNS lymphoma
from other malignant CNS conditions [7]. This claim was
based on an AUC value of AT III in CSF. We evaluated here
the AUC values for AT III, albumin, and the AT III/albumin
ratio. The difference between AT III (AUC=0.791, p=0.002)
and albumin (AUC=0.839, p<0.001) was not clear, indicat-
ing that AT III is not a novel biomarker that could be used to
select patients with lymphoma from those with other diseases.
The patients in this study were treated with CNS prophy-
lactic therapy due to a high risk of CNS relapse, and there was
also a possibility that some of them primarily had subclinical
CNS disease. This might have influenced the results
concerning AT III concentrations in the CSF. The median
age of the patients was also higher than in the non-
lymphoma patients, which might have had an effect on the
results. There was no evaluation of neurodegenerative dis-
eases in the lymphoma patients. Serum samples were not
available from the patients with neurological conditions, but
it is not likely that this would have had an impact on the
results.
The difference between the present study and the previous
ones [7, 8] is that we used both PCNSL patients and systemic
lymphoma patients without CNS involvement as a lymphoma
group. Despite the fact that in these cases lymphoma affected
brain or nodal areas only, it seems that CSFAT III concentra-
tions are higher in cases of lymphoma. The biology of the
process needs further study. It might be that CSF AT III is
involved in inflammatory conditions [16].
In summary, in the present study, we found that elevated
CSF AT III levels in patients with CNS involvement of lym-
phoma reflect the magnitude of blood–brain barrier disruption
andAT III is not an independent biomarker of lymphomaCNS
involvement.
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